Clay Siegall, PhD is a cancer scientist and pharmaceutical executive. He is the current President, CEO and Chairman of Seattle Genetics. He holds a PhD in Genetics awarded by George Washington University and a BS in zoology from the University of Maryland. Dr. Siegall has had over seventy published papers and holds seventeen patents. As the cofounder of Seattle Genetics, Dr. Siegall has been a driving force in Seagen’s move toward scientific innovation and passion for patient care. It is believed that Dr. Siegall helped to secure over $300 million in funding for his company’s drug research. Dr. Siegall’s company has a current focus on developing antibody-drug coagulates (ADC) including ADCETRIS (bretuximad vedotin) which was approved by the Food and Drug Administration in 2011 for the treatment of cancer. Seattle Genetics completed an initial public offering in March 2001 and is traded under the symbol SGEN. Seattle Genetics has around 600 total employees. In addition to his work with SEAGEN, Dr. Siegall serves on the board of directors for Ultragenyx, Mirna Therapeutics and Alder Biopharmaceuticals. Under Dr. Seigall’s leadership, Seagen has entered into strategic partnerships with Roche, Abbvie, Glaxoklinesmith and Pfizer to further research into ADCs. Dr. Siegall and his company have been reported on by Bloomberg, CNN and Fox News. Before founding Seattle Genetics, Dr. Siegall worked for Bristol-Myers Squibb as well as the National Cancer Institute. Dr. Siegall is the recipient of a number of awards including 2013 university of Maryland Alumnus of the Year, and 2012 Pacific Northeast Earnst and Young Entrepreneur of the Year.